[1]李佳,秦岚,任众,等.131I治疗青少年Graves病的量效分析[J].国际放射医学核医学杂志,2010,34(3):152-155.
　LI Jia,QIN Lan,REN Zhong,et al.An analysis of the dose and the therapeutic effect of 131I in treating youngsters with Graves disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):152-155.
点击复制

131I治疗青少年Graves病的量效分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
34
期数:
2010年第3期
页码:
152-155
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
An analysis of the dose and the therapeutic effect of 131I in treating youngsters with Graves disease
作者:
李佳;  秦岚;  任众;  张又萍
天津市第一中心医院核医学科, 300192
Author(s):
LI Jia;  QIN Lan;  REN Zhong;  ZHANG You-ping
Department of Nuclear Medicine, the First Central Hospital of Tianjin, Tianjin 300192, China
关键词:
格雷夫斯病; 近距离放射疗法; 碘放射性同位素; 青少年
Keywords:
Graves disease; Brachytherapy; Iodine radioisotopes; Adolescent
分类号:
10.3760/cma.j.issn.1673-4114.2010.03.006
摘要:
目的 分析接受131I治疗的青少年Graves病患者的临床资料,探寻适合中国青少年Graves病患者的有效剂量范围.方法 接受131I治疗的青少年Graves病患者共234例,年龄为8~17岁,平均甲状腺质量为(59.0±16.5)g.完善治疗前准备后,根据每克甲状腺组织给予131I的剂量将患者分为5个观察组,A组:1.11~<1.48 MBq/g,B组:1.48~<1.85 MBq/g,C组:1.85~<2.22 MB/g,D组:2.22~2.59 MBq/g,E组:>2.59 MBq/g,观察每组疗效,统计每组治愈率、好转率和甲状腺功能减退症(甲减)发生率.结果 ①234例患者中治愈152例(64.95%)、好转56例(23.93%)、甲减26例(11.11%),其中B组疗效最高.②治愈率:B组、C组、D组间差异无统计学意义(χ2=2.68,P>0.05),B组治愈率显著高于A组及E组(χ2=10.20和χ2=5.49,P<0.05),A组治愈率最低.③好转率:B组、C组、D组及E组间差异无统计学意义(χ2=1.94,P>0.05),A组的好转率显著高于B组、C组、D组和E组(χ2=8.74、χ2=6.68、χ2=7.01和χ2=11.12,P<0.05).④甲减发生率:A组、B组、C组及D组间差异无统计学意义(χ2=2.71,P>0.05),E组的甲减发生率显著高于A组、B组、C组和D组(χ2=12.36、χ2=11.58、χ2=9.37和χ2=4.36,P<0.05).结论 青少年Graves病患者接受131I治疗安全有效,131I治疗的首选剂量建议控制在1.48~2.59 MBq/g,既能获得较满意的疗效又不致于增加甲减发生率.
Abstract:
Objective To analyses the clinical data of 131I in treating youngsters with Graves disease,and to explore the effective dose range which is appropriate for Chinese youngsters with Graves disease.Methods Two hundred and thirty-four youngsters with Graves disease were selected in this study, their ages were between 8 and 17, the average quality of their thyroids was(59.0±16.5)g. According to the absorbed dose of 131I per gram of thyroid gland, 234 patients were divided into five groups: A: 1.11-<1.48 MBq/g, B: 1.48-<1.85 MBq/g,C: 1.85-<2.22 MBq/g,D: 2.22-2.59 MBq/g, E: >2.59 MBq/g. The therapeutic effect was evaluated by observing after treatment. And calculate the recovery rate, the improvement rate and the incidence rate of hypothyroidism. Results ①One hundred and fifty-two (64.95%) patients were cured, 56 (23.93%) were much better than before and 26 (11.11%) were hypothyroid. The therapeutic effect of group B was the best in all groups. ②The recovery rate: there was no significant difference between group B, group C and group D (χ2=2.68, P>0.05). The recovery rate of group B was better than group A and group E (χ2=10.20 and χ2=5.49,P<0.05). The recovery rate of group A was the lowest. ③The improvement rate: There was no significant difference between group B, group C, group D and group E(χ2=1.94, P>0.05). The improvement rate of group A was the highest (χ2=8.74,χ2=6.68,χ2=7.01 and χ2=11.12, P<0.05). ④The incidence rate of hypothyroidism: There was no significant difference between group A, group B, group C and group D (χ2=2.71, P>0.05). Group E had the highest incidence rate of hypothyroidism (χ2=12.36, χ2=11.58,χ2=9.37 and χ2=4.36, P<0.05). Conclusions Using 131I is a safe and effective therapeutic approach for youngsters with Graves disease. We suggest the absorbed dose range of 131I per gram of thyroid gland is 1.48-2.59 MBq/g,which can obtain the better therapeutic effect and can’t increase the incidence rate of hypothyroidism.

参考文献/References:

[1] Wartofsky L Radioiodine therapy for Craves’ disease:case selection and restrictions recommended to patients in North America. Thyroid, 1997,7(2):213-216.
[2] 中华医学会.临床技术操作规范(核医学分册).北京:人民军医出版社,2004:175-177.
[3] 马寄晓.放射性核素治疗的现状与进展.中华核医学杂志,1984,4(1):1-3.
[4] Rivkees SA, Sklar C, Freemark M. Clinical review 99:The management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab, 1998,83(11):3767-3776.
[5] 段东,罗加,倪济苍,等.青少年甲亢131I治疗的临床初探.重庆医科大学学报,2002,27(1):96-99.
[6] Rivkees SA, Cornelius EA. Influence of iodion-131 dose on the outcome of hyperthyroidism in children. Pediatrics, 2003, 111(4):745-749.
[7] Read CH Jr, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab, 2004, 89(9):4229-4233.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,张丽花,蒋宁一.甲状腺癌131I治疗后合并骨髓增生异常综合征一例[J].国际放射医学核医学杂志,2016,40(3):235.[doi:10.3760/cma.j.issn.1673-4114.2016.03.014]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]霍小东,王慧星,阎卫亮,等.血管内皮抑制素对125I近距离照射裸鼠肺癌移植瘤的增敏效应研究[J].国际放射医学核医学杂志,2016,40(5):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
　Huo Xiaodong,Wang Huixing,Yan Weiliang,et al.Sensitization effect of endostatin for 125I brachytherapy on transplanted tumor in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
[5]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[6]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[7]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[8]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[9]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[10]侯朝华,霍彬,宋杨.组织间近距离放射性粒子植入治疗肿瘤的进展[J].国际放射医学核医学杂志,2015,39(4):348.[doi:10.3760/cma.j.issn.1673-4114.2015.04.016]
　Hou Zhaohua,HuoBin,SongYang.Organizational close radioactive seed implantation therapy in treating tumor progression[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):348.[doi:10.3760/cma.j.issn.1673-4114.2015.04.016]
[11]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[12]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
　Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[13]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
　ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[14]牟联超,李先映,石彩虹.131I治疗青少年Graves病58例临床分析[J].国际放射医学核医学杂志,2010,34(5):299.[doi:10.3760/cma.j.issn.1673-4114.2010.05.013]
　MU Lian-chao,LI Xian-ying,SHI Cai-hong.Analyze of 131I therapy on 58 youngsters with Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):299.[doi:10.3760/cma.j.issn.1673-4114.2010.05.013]
[15]查金顺,黄春玲,蒋婷吟,等.131I治疗Graves甲状腺功能亢进症中碳酸锂的应用[J].国际放射医学核医学杂志,2011,35(2):93.[doi:10.3760/cma.j.issn.1673-4114.2011.02.007]
　ZHA Jin-shun,HUANG Chun-ling,JIANG Ting-yin,et al.Application of lithium carbonate on radioiodine treatment of Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):93.[doi:10.3760/cma.j.issn.1673-4114.2011.02.007]
[16]王澎,谭建.不同药物影响Graves病131Ⅰ治疗效果的研究进展[J].国际放射医学核医学杂志,2011,35(1):9.[doi:10.3760/cma.j.issn.1673-4114.2011.01.003]
　WANG Peng,TAN Jian.Advance of study on the influence of different drugs on the efficacy of 131I treatment for Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):9.[doi:10.3760/cma.j.issn.1673-4114.2011.01.003]
[17]孙琦婷,赵德善.Graves病甲状腺功能亢进症与血糖代谢[J].国际放射医学核医学杂志,2010,34(3):143.
　SUN Qi-ting,ZHAO De-shan.Graves disease hyperthyroidism and glycometabolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):143.
[18]汤建林,马万红.131I治疗Graves病合并严重血液系统疾病的时机和方法[J].国际放射医学核医学杂志,2011,35(6):361.[doi:10.3760,cma.j.issn.1673-4114.2011.06.010]
[19]杨凡慧,陈跃,张春银.131I治疗青少年及儿童格雷夫斯甲亢的临床应用随访研究[J].国际放射医学核医学杂志,2017,41(2):98.[doi:10.3760/cma.j.issn.1673-4114.2017.02.004]
　Yang Fanhui,Chen Yue,Zhang Chunyin.Follow-up study on children and adolescents with Graves hyperthyroidism after 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(3):98.[doi:10.3760/cma.j.issn.1673-4114.2017.02.004]

备注/Memo

备注/Memo:
收稿日期:2009-12-28。
通讯作者:李佳(E-mail:huowuyanyangtian@163.com)
更新日期/Last Update: 1900-01-01